Education
About Us
Working with TipRanks
Follow Us
Icon plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$133.28 - $347.72
Previous CloseN/A
Volume330.38K
Average Volume (3M)1.43M
Market Cap
$12.23B
Enterprise Value$20.31B
Total Cash (Recent Filing)$538.78M
Total Debt (Recent Filing)$3.57B
Price to Earnings (P/E)15.9
Beta1.07
Next Earnings
Jul 23, 2025EPS Estimate
3.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.54
Shares Outstanding80,756,860
10 Day Avg. Volume1,994,844
30 Day Avg. Volume1,426,185
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.34
Enterprise Value/Ebitda12.39
Forecast
1Y Price Target
$196.69Price Target Upside35.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAdjusted EBITDA and adjusted EPS beat targets for the quarter.
Stock RepurchaseICON leveraged its strong balance sheet to repurchase $250 million of its stock, reflecting confidence in long-term value.
ValuationICLR is trading at a historically cheap valuation compared to its 5-year average.
Bears Say
Client OrdersRevenue from ICON's top 10 clients decreased by 7.0% in the first quarter, indicating challenges in maintaining client orders.
R&D Cuts And Macro HeadwindsLower expectations for R&D growth at top 20 pharma companies, particularly for ICLR clients, and macro headwinds are likely restricting growth.
Revenue DeclineICON reported first-quarter revenue below analyst estimates, reflecting a decline of 4.3% year-over-year.
---
Ownership Overview
2.00% Insiders
28.17% Mutual Funds
2.03% Other Institutional Investors
66.58% Public Companies and
Individual Investors
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $133.28 and its highest was $347.72 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $12.23B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Jul 23, 2025 which is in 82 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Apr 30, 2025. The company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.102 by $0.088.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 3.3.
How many shares outstanding does Icon plc have?
Icon plc has 80,756,860 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $3.19 in its last earnings report, beating expectations of $3.102. Following the earnings report the stock price went down -4.114%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
---
Icon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$196.69 (35.45% Upside)
$196.69 (35.45% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 232.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $367.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.16%
12-Months-Change
Fundamentals
Return on Equity
8.44%
Trailing 12-Months
Asset Growth
-0.66%
Trailing 12-Months
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
---
ICLR Company Deck
---
ICLR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted the company's achievements in operational efficiency and strategic expansions, particularly in AI and partnerships. However, these positive aspects were overshadowed by significant challenges, including revenue declines, elevated cancellations, and the impact of cancelled COVID trials on guidance. The overall sentiment reflects a cautious outlook due to ongoing market uncertainties.Read More>---
ICLR Stock 12 Month Forecast
Average Price Target
$196.69
▲(35.45% Upside)
Technical Analysis
Labcorp Holdings
―
Revvity
―
West Pharmaceutical Services
―
Penumbra
―
Medpace Holdings
―
---